ARTICLES BY MATTHEW PILLAR

• Inside Interius' Global Regulatory Strategy

  12/13/2024

  Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy.

• 1 In 300 People In The U.S. Is Living With HIV. That's Not Okay With Jeff Galvin.

  2/12/2024

  By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.

• Legal And IP Protection For New Biotechs

  10/31/2023

  Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

• AAV Manufacturing Field: An Interactive Look

  3/17/2023

  Mapping the adeno-associated virus (AAV) therapeutic space gives us a glimpse into indication priorities for gene therapy, and a look at whose got their fingers in which partners’ pots. Check out this interactive graphic from DeciBio Principal Carl Schoellhammer, Ph.D. It's not only instructive, its kind of therapeutic to play with. 

• From Sales To The C-Suite Of Pioneering Gene Therapy

  11/15/2022

  AviadoBio is building a pipeline of investigational gene therapies for neurodegenerative diseases. Its lead preclinical candidate is AVB-101 for GRN frontotemporal dementia (FTD-GRN). It’s an intra-thalamic gene supplementation therapy, and as it heads to clinical trials, it's being overseen by a ladder climber who's seen it all.

• Biomanufacturing Capacity Crunch: It's The Supply Chain's Fault

  10/7/2022

  What's behind the protracted biopharma manufacturing capacity crunch, when will it end, and what are manufacturers doing to keep supply on track? During Biotech Week in Boston ad BioProcess International, CDMOs and sponsors weighed in.

• AAV Gene Therapy Takes On Kidney Disease

  7/6/2022

  Built on the back of Prof. Moin Saleem’s two decades of cellular-level kidney research, Purespring Therapeutics is reimagining the treatment of kidney diseases that affect nearly a billion people worldwide. The company is preparing a first-of-its-kind AAV gene therapy candidate for the clinic. 

• CBER's Peter Marks On Complex Biologics Manufacturing Advances

  6/30/2022

  At ISPE’s 2022 Biotechnology Conference In Boston, CBER Director Dr. Peter Marks kicked off three days of programming with reflections on the COVID-19 pandemic as a catalyst to advanced manufacturing in biologics, sharing his vision for industry and the role of the FDA.

• IPSCs For Democratized Cell Therapy

  6/7/2022

  Dr. Daniel Teper and his team at Cytovia Therapeutics have developed a unique combination of candidates designed to improve access to safe and affordable "off-the-shelf" cell therapies. Founded just four years ago, the company is preparing multiple clinical trials of IPSC-derived therapies, which Dr. Teper says lend to a consistent, scalable manufacturing process. 

• How To Build A Genomic Medicine Biotech

  5/11/2022

  SparingVision CEO Stephane Boissel took the reins of a fledgling, single-asset gene therapy company born of academic research and quickly built a well-funded startup with a deepening pipeline of ocular disease candidates. He told the Business of Biotech how it happened.

• The CAR T Speed Show

  5/9/2022

  Some mainstream, high-profile research out of the University of Pennsylvania has re-energized emerging cell therapy developers’ focus on manufacturing and administration speed. Speedy cell therapy pioneer EXUMA Biotech provides an update on its approach.

• Gene Cargos: Building A Bigger Ship

  5/6/2022

  Dissatisfied with the limitations of AAV gene editing, Drs. Ray Tabibiazar and Joe Higgins launched SalioGen, a company with an ambitious goal: the safe delivery of large strands of DNA cargo that mimics the way it happens in nature. 

• Ocular + Auditory Cell Therapies: Lineage Cell Therapeutics 2.0

  4/25/2022

  On the heels of a lucrative deal with Roche/Genentech for its Phase I/IIa dry age-related macular degeneration candidate, Lineage Cell Therapeutics is fording new waters with a promising auditory neuropathy spectrum disorder candidate. CEO Brian Culley shares the strategy.

• CAR T-cell Therapy, Vaccines To Address Breast, Ovarian Cancers

  4/20/2022

  In partnership with the Cleveland Clinic and Moffitt Cancer Centers, Anixa Biosciences moves into Phase 1 trials of its innovative approaches to treating and preventing all-too-prevalent cancers in women.

• Inside The Allogeneic NK Cell Therapy Effort

  3/21/2022

  With its genetically engineered induced pluripotent stem cell-derived allogeneic natural killer cell technology, Shoreline Biosciences aims to overcome what Chairman and CEO Kleanthis Xanthopoulos calls the tallest barrier in the space: patient accessibility.